JP2015500836A - 腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物 - Google Patents

腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物 Download PDF

Info

Publication number
JP2015500836A
JP2015500836A JP2014546156A JP2014546156A JP2015500836A JP 2015500836 A JP2015500836 A JP 2015500836A JP 2014546156 A JP2014546156 A JP 2014546156A JP 2014546156 A JP2014546156 A JP 2014546156A JP 2015500836 A JP2015500836 A JP 2015500836A
Authority
JP
Japan
Prior art keywords
opn
variant
cancer
seq
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500836A5 (enExample
Inventor
リットリング，スーザン，アール．
ラングボー ヴェイス，ペータ
ラングボー ヴェイス，ペータ
セレーナ，アンヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
ADA Forsyth Institute Inc
Original Assignee
Arla Foods AMBA
Forsyth Dental Infirmary for Children Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA, Forsyth Dental Infirmary for Children Inc filed Critical Arla Foods AMBA
Publication of JP2015500836A publication Critical patent/JP2015500836A/ja
Publication of JP2015500836A5 publication Critical patent/JP2015500836A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014546156A 2011-12-07 2012-12-07 腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物 Pending JP2015500836A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161567899P 2011-12-07 2011-12-07
US61/567,899 2011-12-07
US201261673912P 2012-07-20 2012-07-20
EP12177329 2012-07-20
US61/673,912 2012-07-20
EP12177329.5 2012-07-20
PCT/US2012/068628 WO2013086459A1 (en) 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Publications (2)

Publication Number Publication Date
JP2015500836A true JP2015500836A (ja) 2015-01-08
JP2015500836A5 JP2015500836A5 (enExample) 2016-02-12

Family

ID=48574961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546156A Pending JP2015500836A (ja) 2011-12-07 2012-12-07 腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物

Country Status (12)

Country Link
US (1) US20150344534A1 (enExample)
EP (1) EP2788015A1 (enExample)
JP (1) JP2015500836A (enExample)
KR (1) KR20140104474A (enExample)
CN (1) CN104080472A (enExample)
AR (1) AR089136A1 (enExample)
AU (1) AU2012347468A1 (enExample)
BR (1) BR112014013565A2 (enExample)
CA (1) CA2858379A1 (enExample)
EA (1) EA201491010A1 (enExample)
WO (1) WO2013086459A1 (enExample)
ZA (1) ZA201404920B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001092A1 (en) * 2013-07-05 2015-01-08 Arla Foods Amba Mammalian milk osteopontin for enhancing immune responsiveness
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517284A (ja) * 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
JP2004510742A (ja) * 2000-10-05 2004-04-08 ニュージーランド　デアリー　ボード 乳汁から誘導された骨の健康用組成物
JP2007505610A (ja) * 2003-09-18 2007-03-15 アルラ・フーズ・エイ・エム・ビィ・エイ 幼児用調製乳
JP2008115194A (ja) * 1992-08-13 2008-05-22 2458781 Canada Inc 癌の予防または治療用医薬組成物
WO2009052286A1 (en) * 2007-10-16 2009-04-23 Ventana Medical Systems, Inc. Grading, staging, and prognosing cancer using osteopontin-c
JP2010505409A (ja) * 2006-10-06 2010-02-25 ジャンルカ メック， タンパク質活性化因子を含む栄養補助食品

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
PT1244702E (pt) * 2000-01-07 2006-08-31 Arla Foods Amba Processo para o isolamento da osteopontina do leite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008115194A (ja) * 1992-08-13 2008-05-22 2458781 Canada Inc 癌の予防または治療用医薬組成物
JP2003517284A (ja) * 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
JP2004510742A (ja) * 2000-10-05 2004-04-08 ニュージーランド　デアリー　ボード 乳汁から誘導された骨の健康用組成物
JP2007505610A (ja) * 2003-09-18 2007-03-15 アルラ・フーズ・エイ・エム・ビィ・エイ 幼児用調製乳
JP2010505409A (ja) * 2006-10-06 2010-02-25 ジャンルカ メック， タンパク質活性化因子を含む栄養補助食品
WO2009052286A1 (en) * 2007-10-16 2009-04-23 Ventana Medical Systems, Inc. Grading, staging, and prognosing cancer using osteopontin-c

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRAMWELL VIVIEN H C: "SERIAL PLASMA OSTEOPONTIN LEVELS HAVE PROGNOSTIC VALUE IN METASTATIC BREAST CANCER", CLINICAL CANCER RESEARCH, vol. V12 N11, JPN5015001989, 1 June 2006 (2006-06-01), US, pages 3337 - 3343, ISSN: 0003392156 *
KYEONG-NAM YU: "AEROSOL DELIVERY OF SMALL HAIRPIN OSTEOPONTIN BLOCKS 以下省略", PLOS ONE, vol. V5 N12, JPN5015001988, 22 December 2010 (2010-12-22), US, pages 15623, ISSN: 0003392155 *
L R RODRIGUES: "THE ROLE OF OSTEOPONTIN IN TUMOR PROGRESSION 以下省略", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, vol. V16 N6, JPN5015001993, 1 June 2007 (2007-06-01), pages 1087 - 1097, ISSN: 0003392160 *
TAKAFUJI V: "AN OSTEOPONTIN FRAGMENT IS ESSENTIAL FOR TUMOR CELL 以下省略", ONCOGENE, vol. V26 N44, JPN5015001994, 1 September 2007 (2007-09-01), GB, pages 6361 - 6371, ISSN: 0003392161 *
VALENTINA DONATI: "OSTEOPONTIN EXPRESSION AND PROGNOSTIC SIGNIFICANCE IN NON - SMALL CELL LUNG CANCER", CLINICAL CANCER RESEARCH, vol. V11 N18, JPN5015001991, 15 September 2005 (2005-09-15), pages 6459 - 6465, ISSN: 0003392158 *
WAI PHILIP Y: "THE ROLE OF OSTEOPONTIN IN TUMOR METASTASIS", JOURNAL OF SURGICAL RESEARCH, vol. V121 N2, JPN5015001992, 1 October 2004 (2004-10-01), US, pages 228 - 241, ISSN: 0003392159 *
WEBER GEORG F: "THE METASTASIS GENE OSTEOPONTIN: A CANDIDATE TARGET FOR CANCER THERAPY", BBA-REVIEWS ON CANCER, vol. V1552 N2, JPN5015001990, 28 December 2001 (2001-12-28), NL, pages 61 - 85, ISSN: 0003392157 *

Also Published As

Publication number Publication date
US20150344534A1 (en) 2015-12-03
AU2012347468A1 (en) 2014-06-26
BR112014013565A2 (pt) 2019-09-24
AR089136A1 (es) 2014-07-30
CN104080472A (zh) 2014-10-01
WO2013086459A1 (en) 2013-06-13
KR20140104474A (ko) 2014-08-28
EP2788015A1 (en) 2014-10-15
CA2858379A1 (en) 2013-06-13
ZA201404920B (en) 2015-12-23
EA201491010A1 (ru) 2015-01-30

Similar Documents

Publication Publication Date Title
US20240301022A1 (en) Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
WO2022150633A1 (en) Combination therapy for neuroendocrine tumors
KR102269666B1 (ko) 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물
KR20170093737A (ko) 혈관내피성장인자를 과발현한 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
JP2015500836A (ja) 腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物
US20150190460A1 (en) Osteopontin peptide fragments for use in suppression or prevention of tumor growth
US20230255948A1 (en) Combination Therapy for Cancer
CN114040751A (zh) 针对微卫星稳定型结直肠癌通过协同性免疫原性细胞死亡促进抗肿瘤响应的槲皮素和土木香内酯的纳米共递送
TW200803835A (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20210154265A1 (en) Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment
KR102370176B1 (ko) HopQ를 포함하는 암전이 억제용 조성물
KR101552021B1 (ko) Rab5 발현 저해 물질을 유효 성분으로 포함하는 파브리 질환의 예방 또는 치료용 조성물
Li et al. Pharmacologic evidence of green tea in targeting tyrosine kinases
KR20210106513A (ko) 편평 세포 암종을 위한 요법
WO2019213217A1 (en) Methods and compositions for treatment of cancer with parp inhibitors
EP4005583A1 (en) Cp2c-targeting peptide-based anticancer agent
KR101608141B1 (ko) 클라스린 발현 저해 물질을 유효 성분으로 포함하는 파브리 질환의 예방 또는 치료용 조성물
JP6841427B2 (ja) スクレロスチンを用いた悪性骨腫瘍の治療又は予防
US9801840B1 (en) Pharmaceutical composition and use thereof
KR20220053506A (ko) 실리마린 매개된 셀레늄 나노입자 및 이의 용도
KR20220153434A (ko) 쿠드락산톤 b를 포함하는 혈전증의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20140723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170620